Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America

BACKGROUND: The prognosis of children with juvenile dermatomyositis (JDM) has improved remarkably since the 1960’s with the use of corticosteroid and immunosuppressive therapy. Yet there remain a minority of children who have refractory disease. Since 2003 the sporadic use of biologics (genetically-...

Descripción completa

Detalles Bibliográficos
Autores principales: Spencer, CH, Rouster-Stevens, K, Gewanter, H, Syverson, G, Modica, R, Schmidt, K, Emery, H, Wallace, C, Grevich, S, Nanda, K, Zhao, YD, Shenoi, S, Tarvin, S, Hong, S, Lindsley, C, Weiss, JE, Passo, M, Ede, K, Brown, A, Ardalan, K, Bernal, W, Stoll, ML, Lang, B, Carrasco, R, Agaiar, C, Feller, L, Bukulmez, H, Vehe, R, Kim, H, Schmeling, H, Gerstbacher, D, Hoeltzel, M, Eberhard, B, Sundel, R, Kim, S, Huber, AM, Patwardhan, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470177/
https://www.ncbi.nlm.nih.gov/pubmed/28610606
http://dx.doi.org/10.1186/s12969-017-0174-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470177/
https://www.ncbi.nlm.nih.gov/pubmed/28610606
http://dx.doi.org/10.1186/s12969-017-0174-0

Ejemplares similares